Skip to main content

Silexion Therapeutics Corp DEFA14A, filed Oct 19, 2026

Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics Corp (Nasdaq: SLXN) adjourned its October 19, 2026 extraordinary general meeting to October 26, 2026, to vote on increasing authorized share capital by 500,000,000 ordinary shares and authorizing a reverse share split of 1-for-15 to 1-for-25 to regain Nasdaq compliance. AI summary

DEFA14A 2026-10-19
View Original
Added on October 19, 2026